相关实验视频
Updated: Jan 17, 2026

05:25
Author Spotlight: Enhancing Coronary Artery Revascularization
Published on: September 15, 2023
1.2K
导航多细胞血症和X因子缺乏在冠状动脉旁路移植的心肺旁路:一个案例报告
Jenna L Cornibe1, Arthur H Katz2
1Jupiter Medical Center, 1210 S Old Dixie Hwy, Jupiter, FL 33458, USA - Perfusion Services, Epic Specialty Staffing, 2250 McGregor Blvd Suite 3300, Fort Myers, FL 33901, USA.
The journal of extra-corporeal technology
|September 15, 2025
概括
本案例研究详细介绍了一种成功的心肺旁路手术 (CPB) 对于患有多细胞血病 (PV) 和X因子缺乏症的患者进行冠状动脉旁路移植,突出了一个罕见但可管理的临床情景.
科学领域:
- 心脏病学 心脏病学
- 血液学 血液学 血液学
- 手术科学 手术科学
背景情况:
- 多细胞血病 (PV) 和X因子缺乏症是罕见的疾病.
- 患有PV和出血障碍同时存在的患者对心脏手术提出了独特的挑战.
- 这类患者心肺绕道术 (CPB) 的文献有限.
研究的目的:
- 在患有同时存在PV和X因子缺乏症的患者中报告成功的CPB管理.
- 强调在管理复杂的外科病例时采用多学科方法的重要性.
- 为了为CPB在PV患有出血障碍的患者的稀缺文献做出贡献.
主要方法:
- 一名确诊患有真多细胞血症和X因子缺乏症的患者接受了冠状动脉旁路移植.
- 心肺绕道 (CPB) 被用于手术程序.
- 一个多学科的团队管理了患者的护理,专注于静血和电路管理.
主要成果:
- 在没有重大并发症的情况下,CPB运行成功完成.
- 患者的凝血参数和血液状况受到密切监测和管理.
- 在体外电路内没有观察到氧化器故障或血栓形成的情况.
结论:
- 在患有同时存在的真多细胞血症和X因子缺乏症的患者中,可以获得成功的CPB.
- 一个细致的,多学科的方法对于优化这些复杂的案例的结果至关重要.
- 这个案例为有限的了解增加了有价值的数据CPB管理在PV患者罕见的出血障碍.
相关概念视频
Cardiomyopathy VII: Pre and Post Operative Nursing Management
288
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
288
Cardiomyopathy II: Dilated Cardiomyopathy
480
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
480
Cardiomyopathy V: Interprofessional Care
339
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
339
Cardiomyopathy VI: Nursing Management
314
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
314
Cardiopulmonary Resuscitation IV: Pharmacological Management
675
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
675
Heart Failure VI: Adjunct Therapies
261
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
261

